Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 7/20 | 0.32 |
| ▸ | HNF4A | P41235 | 4/20 | 0.32 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5846268 | 0.82 | RXRA (0.36) | RXRAHNF4ACYP26A1 | |
| SCHEMBL6033023 | 0.80 | — | — | |
| SCHEMBL7752265 | 0.80 | RXRA (0.33) | RXRAHNF4APPARG | |
| SCHEMBL6033477 | 0.76 | RARG (0.48) | RXRAHNF4ACYP26A1PPARG | |
| SCHEMBL8005483 | 0.76 | RXRA (0.50) | RXRAHNF4A | |
| SCHEMBL5366510 | 0.73 | RXRA (0.45) | RXRA | |
| SCHEMBL5364822 | 0.73 | RXRA (0.48) | RXRAHNF4APPARG | |
| SCHEMBL6033476 | 0.72 | RXRA (0.34) | RXRAHNF4ACYP26A1 | |
| SCHEMBL6032616 | 0.71 | RXRA (0.47) | RXRAHNF4ACYP26A1 | |
| SCHEMBL6479338 | 0.71 | RXRA (0.47) | RXRAHNF4APPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992094-B1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-31 | — | — | US | disclosed |
| US-20060014803-A1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-19 | — | — | US | disclosed |
| EP-1086080-B1 | DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2004-08-25 | — | — | EP | disclosed |
| US-6313162-B1 | FOR USE IN HUMAN OR VETERINARY MEDICINE SUCH AS DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR AND OPHHALMOLOGICAL DISORDERS; AND IN COSMETICS | CENTRE INTERNATIONAL DE RECHERCHE DERMATOLOGIQUES GALDERMA (C.I.R.D.) GALDERMA (FR) | 2001-11-06 | — | — | US | disclosed |
| EP-1086080-A1 | DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | Galderma Research & Development, S.N.C. (FR) | 2001-03-28 | — | — | EP | disclosed |
| EP-0832057-B1 | DIAROMATIC PROPYNYL OR DIENYL COMPOUNDS | CT INTERNAT DE (FR) | 2001-01-03 | — | — | EP | disclosed |
| US-6046220-A | ADMINISTERING TO THE PATIENT A PROPYNYL OR DIENYL BIAROMATIC COMPOUND TO TREAT A SKIN DISORDER, INFLAMMATORY CONDITIONS, VISION DEFECTS, ALOPECIA, CARDIOVASCULAR DISORDER, CANCER OR PRECANCER AND INSULIN DEPENDANT DIABETES | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-04-04 | — | — | US | disclosed |
| WO-1999065872-A1 | DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014803-A1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | TYR, DERL1, GPX1 | RXRA 1865/4885HNF4A 4062/4885CYP26A1 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.